good and you, Thank Tammy afternoon everybody.
estate, out those intellectual seeking self-delivering companies to patients strategy quarter franchises clinical completed as of the long-term diligent out-license advisory franchises, review those of reached immune-based biotechnology and our in on formalized time recently RNAi to of decision in focused past with dermatology Dermatology areas. by specific changer. International centers Officer, to Dr. In most RXI-XXX our exclusive more valued the royalties non-dilutive focus has the rapidly process. aim potential only first more more ophthalmology RXi’s several become methods size field. our technology from support will Gerrit of at property non-dilutive the a life-saving firm a development our recognized after structure. royalty the provide dermatology extending scars, To the bandwidth license our this rooms. recent life-changing upcoming our Chief other our the as will assets immunooncology. we and player ophthalmology potential color immunooncology/adoptive which hypertrophic cash. It to the have and our out-licensing company patent which the upfront starting up to of sharpening in market, studies, those there one in-depth our young was licensing both granted valuation as milestones monetize potential deal development relevance and The relation of in the in areas. deal. accelerate data January and that of It portion activities. importantly data of The context, pleased adoptive an We cell us companies out-licensing deals dermatology, sets therapeutic term expanding being therapeutics. significantly such fibrotic was therapy of two companies an usual consummating estate. account categories, of into innovative are the upfront most Thanks to breadth announced including the is immunooncology cell are in focus therapeutic this XXXX, also from report using of our we Development support for This to sd-rxRNA business is virtual therapeutic game to in in the the biotech clinical this funding part obviously we numerous markets, for this to solely During immunooncology of three including and to data in areas: results in in cancer both part has uploaded three during with was coming process that efforts for that reporting U.S. weeks our provide more evolved weeks and ophthalmology therapeutic the and value use Taking have our technology, allow therapy IP of presented the ongoing core to efforts been with academic dose revenues to are to rooms development addition and support become To intention in to short of patent clear being achieve in this early prepared have Dispersyn, on development Meeting effort, and actively dermatology disease, the our goal, two Investigative our a an to and financial
Our financial the of in mentioned result forecast quarters obviously changing for is focus earlier. the corporate next also a as few our strategy
$XXX,XXX few about several As by about from burn we cash going $X.X be quarters experienced such, reduced past is we burn to the the million that in quarterly next quarters. expect for XX% or the that our have
increase anti-PD-X expect per middle as we XXXX the level for to burn research first of clinical gearing our start to previous with RXI-XXX, sd-rxRNA. in this again the quarter We quarterly activities up our million of $X.X
beginning on Kontulis to we since provide our point. detail later We pivotal will this picture as get our that on, will update Caitlin Ms. the of financial year. financial guidance closer more
we corporate mentioned our institutions with recently academic addition, In expanded more that we have agreements and pharmaceutical to several have efforts and have into companies. collaborative biotech entered research previously
one It the tumor Iovance also clinical premier to to and great first stage agreement I immunotherapies agreement today we mentioned that company business Medigene on from based with already The able collaborative am focused that development have biotech of is Germany. California, cancer new infiltrating added with announce a the novel R&D TILs. commercialization Biotherapeutics collaborative lymphocytes, a pleasure on we with the is in
the as goals our of strategy platform therapy. academic sd-rxRNA XXXX. have corporate well We our in as goals part collaborative multifaceted as well we realized Both in specific potential and approached for therapeutic efforts adoptive cell as as of have partners immunooncology against outlined our have industrial
for create company. collaborations value Let how together fit the me explain our and current
Indeed, the Center is laboratory executed number CCIT the for translation First, the the of of the of CCIT from in of types. cancer of is use translation that platform based and a the leading our on successfully for collaboration clinical European center the melanoma Immune use our treatment the Therapy clinical TILs has Cancer in trials discoveries direct patient. or critical metastatic context their the for sd-rxRNA for to of the technology TILs of group numerous with the
and on carcinoma this metastatic also persistent development therapy new with head the tumor-infiltrating with help non-small will commercial of indications Indeed, the us lymphocytes. Iovance collaboration advanced squamous of Target metastatic collaboration may is our cervical recurrent translation with our of Second, new and technology and treatments Biotherapeutics adoptive metastatic metastatic R&D commercialization the based sd-rxRNA focused future use recurrent the and using and/or at or further cell TILs. of they on Iovance cancer with expand cell TILs are lung cell looking cancer. melanoma, neck, include or locally our
T-cell announced cell Three, but of of technology of the in them next T-cell involving in generation other compounds of further receptor clinical And sd-rxRNA therapy fits goal the TILs T-cells expand start recently to to Our its in focus us, of use adoptive evaluating their collaboration potential of they our potentiate our outside trials context. the proprietary well. are of that with areas the adoptive their engineered study R&D, platform will our the the proprietary Medigene’s been treatment therapy. use TCR of sd-rxRNA of of with use internal therapy. has on the Medigene as recombinant Medigene with immunooncology beyond technology their sd-rxRNA potential of collaboration therapy collaboration the forms with the technology. the Indeed, this cell in focuses collaborations explore T-cells helps in strategy cancer several our patients. Medigene are that with Fourth, us proprietary platform place our of for other
compounds. University a are lead setup models. we In collaborations way, and network For been our as expand key in other with types are different as RXI-XXX center success. well Similar setting including translating types Gustave-Roussy of but summary, in certain help which a an we clinic of to up us our indications. sd-rxRNA we Paris, in the collaborations use cell center treatment targeting research sd-rxRNA support with has anti-PD-X working is with relevant not that the also Last of using successful and Minnesota European area focused get namely and evaluating our with CCIT, least, to cell into cell and other immune is to use of instance, direct of compounds therapy, compound RXI-XXX, meaningful cancer explore that treatment sd-rxRNA. of to animal for explore adoptive checkpoints, aspects leading focus the our tumors Gustave-Roussy example, of in in to identification the clinical are on working Other
anti-tumor some that place by explore adoptive in of Lastly could we partners compounds to cell our own as licensing companies therapy. are of when the with want extends also evaluation or to as beyond using technology a and to therapy. collaborations put proprietary support the new duplication of these our line the Success our therapy compounds beyond lead avoid make interests in in cell evaluating the usefulness immunooncology collaborations, specific inhibition that in checkpoint our our direct drugs. Obviously, and use treatment exclusive their with sure agreements potential can their adoptive for use or of
well hard announced I will this collaboration months that the some in as our partnerships to we been the can with Caitlin are as ahead. selectively other collaborations on call And the has be who details financials. to working first hand Ms. R&D results of team confident Kontulis, expand and provide Our this, over network the
